David Ritchie, MD, PhD, discusses immunological recovery with venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma.
David Ritchie, MD, PhD
Advertisement
Articles by David Ritchie, MD, PhD
David Ritchie, MD, PhD, discusses the rationale of the AIM trial in relapsed/refractory mantle cell lymphoma (MCL).
David Ritchie, MD, PhD, discusses the immunologic impact of long-term venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.
David Ritchie, MD, PhD, discusses the long-term immunological response to the combination of venetoclax and ibrutinib in relapsed/refractory mantle cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Ritchie on Immunological Response to Venetoclax/Ibrutinib in R/R MCLPublished: February 6th 2020 | Updated:
Dr. Ritchie on the Immunologic Impact of Long-Term Venetoclax/Ibrutinib in R/R MCLPublished: February 8th 2020 | Updated:
Dr. Ritchie on the Rationale of the AIM Trial in Relapsed/Refractory MCLPublished: February 18th 2020 | Updated:
- Dr. Ritchie on Immunological Recovery With Venetoclax and Ibrutinib in MCL
Published: March 5th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5